and ScaleDown (KYW), Chicago, Illinois Purpose: We evaluated agreement between patient reported urinary function and bother, and sexual function and bother in patients treated with radical prostatectomy to help inform possible nonfunctional, modifiable mechanisms for patient bother. Materials and Methods: Patients were recruited from 2011 to 2014 at Washington University, and Brigham and Women's Hospital. Urinary and sexual outcomes were assessed by EPIC-50 (Expanded Prostate Cancer Index Composite-50) before, 5 weeks and 12 months after radical prostatectomy. Spearman rank correlation coefficients and agreement/disagreement categories were used to describe the relation between function and bother. Results: Despite moderate to good agreement between function and bother (urinary r ¼ 0.51e0.69 and sexual r ¼ 0.65e0.80) discordant groups were observed. In the urinary domain these groups were men disproportionately bothered by function at baseline (16.9%) and 12 months after radical prostatectomy (6.1%) and men less bothered by function 5 weeks (26.8%) and 12 months (9.9%) after radical prostatectomy. Discordant groups in the sexual domain were men less bothered by function at baseline (20.8%), and 5 weeks (21.1%) and 12 months (15.7%) after radical prostatectomy. Splitting the urinary bother scale into 2 subscales, including one for incontinence related bother to complement the urinary function scale which measures only incontinence, and one for voiding dysfunction related bother yielded considerably better agreement (urinary function and incontinence related bother r ¼ 0.78e0.83). Factors contributing to the group less bothered by sexual function were unclear. Conclusions: When using EPIC-50, investigators should consider splitting the urinary bother scale by the relation to incontinence to prevent distortions of function-bother and comparisons before vs after radical prostatectomy by coexisting voiding dysfunction. No direct or indirect commercial incentive associated with publishing this article.
PROSTATE cancer is the most commonly diagnosed cancer in developed countries and the second most frequently diagnosed cancer in men worldwide. 1 In developed countries most men present with early stage disease, when a number of curative therapeutic options exist (eg RP and brachytherapy) and survival rates are high. Therefore, an important No direct or indirect commercial incentive associated with publishing this article.
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* factor on which patients base treatment decisions and an important determinant of patient satisfaction with care are the side effects of therapy. 2, 3 As such the importance of assessing patient reported outcomes, including treatment side effects and HRQOL, has gained recognition in the PCa field. The science of improving PCa related PROs has advanced rapidly in the last 20 years. 4 One such PCa related PRO is EPIC. This PRO, which is one of the most commonly used questionnaires in urological research, 5 measures the side effects and associated HRQOL of PCa therapies. 3,6e8 It was revised from the validated UCLA-PCI to create a longer 50-item index, EPIC-50, as well as the shorter 26-item EPIC-26 and the 16-item EPIC-CP (EPIC for Clinical Practice) indexes. EPIC-50 index addresses 4 HRQOL domains, including urinary and sexual side effects, which are common following RP, as well as bowel and hormonal side effects, which are more common following radiation and androgen deprivation therapy, respectively. 9 Each domain includes subscales for the functional side effects of therapy (function) and the annoyance created by these side effects (bother). Nevertheless, most research has focused on patient function, at least for RP, whereas considerably less research has focused on patient bother or satisfaction with function. 4 Additionally, few studies have examined the degree of concordance or perhaps more importantly the discordance between function and bother to identify possible nonfunctional mechanisms of bother (ie instances when bother does not match function) and, thus, identify possible modifiable targets to improve patient satisfaction following RP. Therefore, we used data from the PIE study, a longitudinal study of PCa survivors, to examine the relation between function and bother for urinary and sexual outcomes.
MATERIALS AND METHODS

Study Population
Men scheduled to undergo RP for clinically diagnosed PCa were recruited in the PIE study from 2011 to 2014 at Washington University School of Medicine, and Brigham and Women's Hospital. All scheduled men were eligible for inclusion except those who had previously undergone PCa therapy, radiation therapy to the pelvis (including bladder, rectum or prostate), major pelvic surgery or placement of a penile implant or artificial urinary sphincter. Men with known urethral stricture or colostomy, men who required chronic urinary catheterization and men who did not speak English were also excluded from analysis.
Study Design
Patient reported urinary and sexual outcomes were assessed at baseline before RP, and 5 weeks and 12 months after RP by EPIC-50. 9 We used each of these time points in our analysis to explore the relation between function and bother across the full range of possible values (ie the highest value before RP, the lowest value 5 weeks after RP and an intermediate value 12 months after RP). Although EPIC-50 was developed and validated in PCa survivors an average AE SD of 25.7 AE 13.0 months after primary therapy, it has been widely used to monitor PCa specific PROs before and after RP beginning 1 month after surgery.
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For each EPIC subscale a summary score was calculated and then transformed linearly to a 0 to 100 scale with higher scores indicating better function and less bother. Agreement between function and bother was illustrated by scatterplots and described by the Spearman rank correlation coefficient. Levels of agreement or disagreement between function and bother were defined in relation to previously published MIDs in PCa survivors, including 5 to 9 in the urinary domain and 10 to 12 in the sexual domain. 16, 17 Although these values were derived from UCLA-PCI and EPIC-26 rather than from EPIC-50, the high 0.96 to 1.00 correlation between EPIC-26 and EPIC-50 18 suggests that these MIDs likely also apply to EPIC-50. 16 In our analysis we used the upper bounds of the MID ranges, which were 9 in the urinary domain and 12 in the sexual domain, to provide conservative estimates of disagreement between function and bother. Scatterplots were color coded to distinguish 3 levels of agreement or disagreement, including 1) comparable function and bother, 2) the MID between function and bother, and 3) a large difference between function and bother (ie 2 or more times the MID).
The PIE study was approved by the institutional review boards at Washington University School of Medicine, and Brigham and Women's Hospital. All participants provided informed consent.
RESULTS
Of the 426 eligible participants who completed the baseline survey before RP we excluded 22 who received additional therapies during followup and 55 who did not complete surveys at 5 weeks and 12 months, leaving 349 of 404 (86.4%) eligible participants. Of these men 313 provided complete information on urinary outcomes at all 3 time points and 294 provided complete information on sexual outcomes. Participant mean age was 60.6 years (range 42 to 78). Of the participants 93.8% were Caucasian, 85.0% had completed some college education or more, 62.8% earned $75,000 or greater per year, 87.2% were married or living with a partner and 76.7% had clinical stage T1 disease (supplementary table, http://jurology.com/).
At baseline before RP most men reported good urinary function (median 100), not much urinary bother (median 89.3), worse sexual function (median 62.8) and more sexual bother (median 75.0).
Five weeks after RP all outcomes were considerably worse. In the urinary domain the median value of function was 56.6 and that of bother was 67.9. In the sexual domain the median values were 13.9 and 25.0, respectively. By 12 months after RP all values had improved greatly in the urinary domain (function and bother median 88.4 and 87.5) and slightly in the sexual domain (function and bother median 28.4 and 37.5, respectively).
When comparing function to bother, moderate to good agreement was observed for urinary and sexual outcomes at baseline (r ¼ 0.51 and 0.80), 5 weeks after RP (r ¼ 0.69 and 0.65) and 12 months after RP (r ¼ 0.58 and 0.77, respectively, all p <0.05, see table) . 16, 17 In other words, men with better function tended to be less bothered than men with worse function and vice versa.
However, a few distinct groups with differing function and bother were observed at each time point. In the urinary domain these groups were 1) the 16.9% of men who were disproportionately bothered by function at baseline and 2) the 26.8% less bothered by function 5 weeks after RP. Each group persisted but was considerably smaller 12 months after RP (6.1% and 9.9%, respectively, parts a to c of figure) .
In the sexual domain discordant groups of men less bothered by function were observed at all 3 time points, including 20.8% at baseline, 21.1% 5 weeks after RP and 15.7% 12 months after RP (parts d to f of figure). These groups were also observed when we limited analyses to men with good sexual function (EPIC score 60 to 100 19 ) at baseline, including 20.1% 5 weeks after RP and 14.2% 12 months after RP.
To gain some insight into these discordant groups we reviewed all items in the urinary and sexual domains of the EPIC-50 questionnaire. In the urinary domain the function and bother scores comprise items related to incontinence (supplementary Appendix 1, http://jurology.com/). However, the bother scale includes additional items (item 6, d to f) related to irritative/obstructive symptoms. These types of symptoms are commonly observed in men with voiding dysfunction, including BPH, OAB and chronic pelvic pain syndrome. To separate the influence of incontinence from these conditions we split the urinary bother items into 2 subscales, including one for incontinence related bother and the other for bother related to irritative/obstructive symptoms (supplementary Appendix 1, http://jurology.com/). This resulted in an improved correlation between urinary function and bother related to incontinence at baseline and 12 months after RP, and a similar correlation 5 weeks after RP. It also highlighted the difference between urinary function and bother related to irritative/obstructive symptoms (see table) . 16, 17 When considering the sexual domain (supplementary Appendix 2, http://jurology.com/), the EPIC sexual function score comprises items related to the ability to engage in sexual activity as well as the frequency of activity, which we hypothesized might be influenced by the availability of a sexual partner. Therefore, we repeated analyses stratified by marital status as a surrogate marker of partner availability. However, we observed no difference in the estimates between married men and those living alone at any of the 3 time points (see table) . 16, 17 Finally, no difference was observed in the percent of discordant groups by post-RP pathology in the urinary or the sexual domain. Thus, no evidence was provided on the roles of decisional regret in the case of low risk disease or acceptance of the side effects of therapy in the case of high risk disease (data not shown).
DISCUSSION
Although moderate to good agreement was observed between urinary and sexual function and bother in our study of PCa survivors, a few distinct discordant groups were observed in each domain before and after RP. In the urinary domain these groups included men who were disproportionately bothered by function at baseline, men less bothered by function 5 weeks after RP and a small yet appreciable number of men in each groups 12 months after RP. Discordant groups in the sexual domain were men less bothered by function at all 3 time points.
Further investigation of the urinary domain revealed that the bothered group was largely explained by differences in the components assessed by the urinary function and bother scales, ie the function scale assesses only incontinence whereas the bother scale assesses incontinence and irritative/obstructive symptoms. Splitting the bother scale into 2 subscales, one for incontinence and one for irritative/obstructive symptoms, resulted in considerably better agreement between urinary function and incontinence related bother alone.
These findings suggest that irritative and obstructive symptoms associated with voiding dysfunction contributed to the discordance between function and bother. With respect to the sexual domain it is unclear which factors contributed to lesser function related bother because our attempt to stratify by marital status as a surrogate marker of partner availability and by pathological stage did not explain this discordance.
The idea of splitting urinary incontinence from irritative/obstructive symptoms in the urinary domain of EPIC is not new. In the original EPIC-50 publication the investigators created 2 additional scales based on factor analyses, including one related to incontinence and the other related to irritative/obstructive symptoms. 9 However, as each of these scales consists of items that measure function and bother, a direct comparison of function to bother is not possible. The same is also true for the shorter version of EPIC, EPIC-26, because that urinary incontinence scale includes items for function and bother. Therefore, given the growing interest in PCa survivorship research on patient satisfaction rather than only on function, 23 we propose that future analyses use function and bother scales specific to incontinence and irritative/obstructive symptoms to facilitate a clearer comparison between function and bother.
In addition to function-bother comparisons, another place where problems may arise when using the original urinary bother scale is in natural history studies that compare values before vs after RP. 24, 25 This comparison may be of concern because the urinary bother scale likely captures different conditions with time. Although we did not collect voiding dysfunction specific measures during PIE, we believe that most urinary bother before surgery was likely due to BPH since the bothered group decreased considerably after RP, which is a therapeutic procedure for BPH. In contrast, 5 weeks after surgery when the continence level of the men was the worst, bother likely captured incontinence as the high degree of incontinence likely dominated the patient perception of bother. Finally, 12 months after surgery when continence had improved, bother likely reflected a combination of incontinence in men with residual incontinence as well as persistent or newly developed voiding dysfunction such as OAB, chronic pelvic pain syndrome and other lower urinary tract symptoms. For instance, in a recent study of patients treated with RP de novo OAB developed in 19% and urinary symptoms such as nocturia developed in 22% during a median 2.7 years of followup. 26 Besides complicating comparisons of function to bother, differences in the conditions captured by the urinary bother scale may potentially lead to misleading trajectories of bother with time. For instance, if participants were more bothered by BPH associated irritative/obstructive symptoms before RP than they were by incontinence related symptoms after RP, this could have resulted in seeming improvements in urinary bother after RP. This type of unexpected finding was recently observed in a retrospective cohort analysis by Murphy et al. 24 They noted significantly improved overall urinary outcomes after RP when summarizing all EPIC-26 urinary items, including urinary incontinence, irritative/obstructive symptoms and overall urinary bother, in men with severe urinary bother before RP. This likely reflected the relief of preRP BPH symptoms by prostatectomy. While these findings can readily be disentangled and interpreted with some thought, splitting the urinary bother scale into 2 subscales, including one for incontinence and one for irritative/obstructive symptoms, would allow for a more straightforward interpretation.
To date most of our discussion has focused on men disproportionately bothered by urinary function before RP. However, an additional distinct group of men identified in our analyses were men less bothered by urinary function 5 weeks and 12 months after RP. This group was likely larger 5 weeks than 12 months after RP because urinary function was considerably worse 5 weeks than 12 months postoperatively. In the sexual domain similar groups of men less bothered by function were also observed at all 3 time points.
Although speculative, we believe that these discordant groups may be explained by better mental preparation for the side effects of therapy (eg realistic expectations for continence and potency following surgery), leading to a lower degree of bother despite large functional declines. 27, 28 In line with this hypothesis Parker et al observed improved short-term (1 week before surgery and the morning of surgery) and longer term (6 weeks, and 6 and 12 months postoperatively) mental and physical outcomes after a brief preoperative stress management intervention in a clinical trial of PCa survivors. 29 Other possible mechanisms that might explain our findings include self-management strategies, support groups or other forms of social support to help men cope with large functional declines after RP. 28 We believe these types of interventions should be investigated further to enable men to maintain HRQOL through the immediate decline and the subsequent recovery of function after surgery. 30 
CONCLUSIONS
In summary our findings suggest that EPIC-50 should be used with caution when assessing urinary bother because its performance may be distorted by coexisting or new onset voiding dysfunction such as BPH (only before RP), OAB, chronic pelvic pain syndrome and other lower tract urinary symptoms. Therefore, we recommend separating the urinary bother scale into 2 subscales, including one for incontinence related bother and the other for irritative/obstructive symptom related bother. This would facilitate the interpretation of function-bother comparisons (ie urinary continence function to urinary continence related bother) and preRP vs post-RP comparisons. Future studies should also consider validating these modifications, extending function-bother investigations to bowel and hormonal domains in patients with PCa who are treated with nonRP modalities and exploring possible psychological mechanisms underlying our observed unbothered discordant groups for the potential to inform interventions aimed at improving posttreatment quality of life.
